Latest news
Tonix Pharmaceuticals Announces FDA Alignment on 3,300‑Participant Adaptive Phase 2 Lyme Study; TNX-4800 Dosing, 2027 Site Delivery - TradingViewTradingView · Mon, 03 Aug 2026 11:23:01 GMTTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. - Yahoo FinanceYahoo Finance · Mon, 03 Aug 2026 11:00:00 GMT5Ws of Adaptive Phase Cooling - Tech BriefsTech Briefs · Wed, 29 Jul 2026 06:33:53 GMT